By Jennifer Chiou
New York, Oct. 11 - Predicant Biosciences obtained $7.5 million in debt financing from Hercules Technology Growth Capital, Inc.
"Predicant's technology can be used to detect disease at its earliest stage, track disease progression, improve the accuracy of diagnosis and predict the efficacy of therapy," Hercules managing director Kathy Conte said in a news release.
Proceeds will go towards the development and marketing of the company's diagnosing technology.
Based in South San Francisco, Calif., Predicant is a life sciences company that develops minimally invasive technology for identifying and assaying protein biomarkers.
| Issuer: | Predicant Biosciences
|
| Issue: | Debt
|
| Amount: | $7.5 million
|
| Investor: | Hercules Technology Growth Capital, Inc.
|
| Announcement date: | Oct. 11
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
